Views:1 Author:Site Editor Publish Time: 2021-10-17 Origin:Site
As aromatic chemical supplier, Wuhan LANDMARK Industrial Co., Ltd. was established in 2012 and is located in Wuhan City, Hubei Province.
The company is a comprehensive high-tech enterprise integrating research, production and sales.
As aromatic chemical supplier, the company specializes in cinnamon series, including cinnamic acid, cinnamaldehyde, cinnamic alcohol, methyl cinnamate, ethyl cinnamate and so on. The company can also accept the customization of other cinnamon derivatives.
As aromatic chemical supplier, the company has the advanced production equipment, modern facilities, domestic advanced production technology and mature quality management system.
As aromatic chemical supplier, the LANDMARK headquarters is located in Dongxihu District, Wuhan City, which is the sub-provincial-level central city of six provinces in central China, with convenient land and water transportation radiating nationwide.
We are a growing company committed to continually enhancing the employee experience and remaining a clean, efficient and safe work environment.
As aromatic chemical supplier, the company has years of experience in the production and development of benzaldehyde downstream products, with 5 master degree engineers, 25 undergraduate technicians, and 3000MT annual output of cinnamaldehyde, 1000MT of cinnamic acid, 600MT of cinnamyl alcohol and 600MT of methyl cinnamate.
As aromatic chemical supplier, the company has passed ISO9001 International Quality Management System certification, and relying on the concept of independent development and joint development of universities, it has in-depth cooperation with major universities and scientific research institutions in Wuhan.
As a result of our quality control measures, our company has also got FDA certificate. In the meantime, it has successively awarded “The Excellent Companie of Integrity Standards”, “Top Ten Outstanding Private Enterprises”, and “The AAA-level Credit Enterprises”, etc.
As aromatic chemical supplier, Founded in 2000, SAIJIN bio is mainly committed to R & D, production and sales of recombinant protein and monoclonal antibody biological drugs. It is a pioneer and leader in China's biomedical industry.
It is the first batch of Biopharmaceutical Enterprises in China and the first biopharmaceutical enterprise in Shanghai to pass the certification of drug production quality management specification (revised in 2010) (GMP in 2010).
As aromatic chemical supplier, the company's first product, qiangke ® (recombinant human type II tumor necrosis factor receptor antibody fusion protein for injection) has been developed for 11 years.
It was approved by the State Food and Drug Administration in April 2011 for the treatment of ankylosing spondylitis. At present, phase III clinical trials of rheumatoid arthritis and psoriasis are under way.
Jonker ® It adopts advanced DNA recombination technology and mammalian cell expression system, and is manufactured through the international leading purification production process. It has the characteristics of high activity, high purity and less impurities.
Another product of SAIJIN biology, the biological drug cg002 for the treatment of osteoporosis, is currently in clinical trials.
At the same time, the company also has a number of new monoclonal antibody products in the preclinical research and development stage.
As aromatic chemical supplier, Bowei company is an enterprise specialized in providing high-level bio pharmaceutical project cro service for customers at home and abroad, and is committed to building a one-stop cdmo service platform.
The main services include research and development of biological macromolecular drugs represented by monoclonal antibodies, experimental design in preclinical and clinical stages, customized production, various release detection and characterization analysis, registration application and consultation.
As aromatic chemical supplier, Bowei biology was established in Shanghai Zhangjiang High Tech Park in early 2014. In May 2015, Bowei biology built a 1700 square meter R & D and pilot production base in Shanghai Zhangjiang international medical park. In March 2017, it also built a 3350 square meter pilot production base, covering one research and development center and two pilot production lines, providing a basis for the R & D and pilot production of biological macromolecular drugs Provide whole process design and one-stop service in preclinical and clinical stages.
The total investment in R & D equipment of the company has exceeded 100 million yuan, and there are nearly 100 R & D teams.
Facing the increasingly fierce competition in the domestic monoclonal antibody industry, one of the strategies of Bowei biology is to focus on the quality research, process development, biological analysis, registration and declaration and other services of monoclonal antibody biological drugs, form misplaced competition and complementary cooperation with large cro companies, adhere to international standards, and always achieve quality first and customer first.